Skip to main content
Schott Pharma logo

Schott Pharma — Investor Relations & Filings

Ticker · 1SXP ISIN · DE000A3ENQ51 LEI · 529900TU48UE99NHEY88 F Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2024-01-26 Annual Report
Country DE Germany
Listing F 1SXP

About Schott Pharma

https://www.schott-pharma.com/en

Schott Pharma is a developer and manufacturer of drug containment solutions and delivery systems for injectable drugs. Serving the pharmaceutical and biotech industries, its portfolio includes prefillable syringes, cartridges, vials, and ampoules. The company provides scientifically proven products designed for the safe storage and administration of medications. Beyond individual components, Schott Pharma offers complete, compatible systems and a range of services, including analytical, development, fill-and-finish, and regulatory support. This integrated approach supports clients from clinical trials through to commercialization, ensuring compatibility across the entire pharma value chain.

Recent filings

Filing Released Lang Actions
Annual financial report 2022/2023 (PDF)
Annual Report Classification · 1% confidence The document is explicitly titled 'Annual Report 2022/2023' for SCHOTT Pharma. It contains comprehensive financial statements, a management report, a supervisory board report, and an independent auditor's report. It covers the full fiscal year and provides detailed financial performance indicators, meeting the criteria for a 10-K (Annual Report). FY 2023
2024-01-26 English
Sustainability Report 2022/2023
Environmental & Social Information Classification · 1% confidence The document is explicitly titled "Sustainability Report 2023" on the first page. The content heavily focuses on ESG topics, including workforce responsibility, environmental responsibility (carbon neutrality targets, emissions reduction), and social responsibility. The table of contents confirms sections like 'Environmental responsibility' and 'Social responsibility'. This directly aligns with the definition of an Environmental & Social Information report (ESG/Sustainability Report). Although it mentions the Annual Report and a non-financial declaration being part of it, this document itself is the dedicated sustainability report, making 'SR' the most appropriate classification.
2024-01-26 English
Jahresabschluss der SCHOTT AG & Co. KGaA (HGB) 2022/2023
Annual Report Classification · 1% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for SCHOTT Pharma AG & Co. KGaA for the fiscal year 2022/2023. It contains detailed financial statements, including the balance sheet (Bilanz), profit and loss statement (Gewinn- und Verlustrechnung), and notes (Anhang). Although it mentions that the report is published on their website, the document itself provides the actual financial data and statements, not just an announcement. Therefore, it is classified as an Annual Report (10-K equivalent for German entities). FY 2023
2024-01-26 German
SCHOTT Pharma 2023 Presentation
Investor Presentation Classification · 1% confidence The document is titled "Q4 / FY 2023 Results presentation" and contains detailed financial figures, performance against guidance for the full year (FY23), strategic updates, capacity expansions, and financial guidance for FY24 and the mid-term. This structure is characteristic of an Investor Presentation (IP) used to communicate annual results to investors, often following the official Earnings Release (ER) or Annual Report (10-K). It is a presentation format, not the full regulatory report itself. Since it focuses on presenting the results and strategy, 'Investor Presentation' (IP) is the most appropriate classification.
2024-01-26 English
SCHOTT Pharma 2023 Präsentation (englisch)
Investor Presentation Classification · 1% confidence The document is titled "Q4 / FY 2023 Results presentation" and contains detailed financial figures, performance against guidance for the full year (FY23), strategic updates, capacity expansions, and financial guidance for FY24 and the mid-term. This structure is characteristic of an Investor Presentation (IP) used to communicate annual results to investors, often following the official Earnings Release (ER) or Annual Report (10-K). It is a presentation format, not the full regulatory report itself. Since it focuses on presenting the results and strategy, 'Investor Presentation' (IP) is the most appropriate classification.
2024-01-26 English
Report Publication Announcement 2024
Report Publication Announcement Classification · 1% confidence The document is titled 'Preliminary announcement of the publication of financial reports' and explicitly states that it is announcing *when* and *where* various financial reports (Annual financial report, Group annual financial report, Group financial report (half-year/Q2)) will be disclosed on future dates (Jan 26, 2024, and June 27, 2024). This structure—an announcement about the future release of reports rather than the reports themselves—perfectly matches the definition of a Report Publication Announcement (RPA). The document length is short (3370 chars), further supporting the 'announcement' classification over the full report classification (like 10-K or IR).
2024-01-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.